NCT06257264 2026-04-22
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
BeOne Medicines
Phase 1 Recruiting
Clinical Trials
9 trialsNCT05238922 2026-04-14
Study of INCB123667 in Subjects With Advanced Solid Tumors
Incyte Corporation
Phase 1 Recruiting
NCT07038369 2026-03-17
A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations
Atavistik Bio, Inc
Phase 1 Active not recruiting
NCT05252416 2025-11-28
(VELA) Study of BLU-222 in Advanced Solid Tumors
Blueprint Medicines Corporation
Phase 1 Terminated
NCT03294694 2025-05-31
Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer
Dana-Farber Cancer Institute
Phase 1 Terminated
NCT04726332 2024-05-14
Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101)
Exelixis
Phase 1 Terminated
NCT05905341 2023-11-08
Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors.
Pfizer
Phase 1 Withdrawn
NCT04498520 2021-05-18
Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer
University of California, San Francisco
Phase 1 Withdrawn
NCT03134638 2021-03-09
A Study of SY-1365 in Adult Patients With Advanced Solid Tumors
Syros Pharmaceuticals
Phase 1 Terminated